**Hikma Pharmaceuticals PLC November 2025 Trading Statement Summary:**
Hikma Pharmaceuticals PLC reaffirmed its 2025 financial guidance and provided updates on its medium-term growth outlook. Key highlights include
1. **Performance Across Segments**
**Injectables** Trading in line with expectations, with strong performance in Europe and MENA. Launched Starjemza® (ustekinumab-hmny) and TyzavanTM (vancomycin). Revenue growth expected at 7-9%, with core operating margin of 32-33%.
**Branded** Strong performance in MENA, driven by oncology and chronic illness treatments. Revenue growth expected at 6-7%, with core EBIT margin near 25%.
**Hikma Rx** Stable performance, supported by complex products. Revenue expected to be flat, with core operating margin around 16%.
2. **Organisational Changes**
Centralised R&D under a global structure, led by Hafrun Fridriksdottir, to accelerate pipeline development and synergies.
Dr Bill Larkins stepped down as head of Injectables
CEO Riad Mishlawi will serve as interim head until a replacement is found.
3. **Full Year 2025 Outlook**
Group revenue growth maintained at 4-6%.
Core operating profit range tightened to $730-$750 million, in line with market expectations.
4. **Medium-Term Outlook (2024-2027)**
Injectables margins expected around 30%, reflecting delays in Bedford facility production due to supply chain challenges.
Group revenue CAGR revised to the lower end of 6-8%.
Core operating profit growth adjusted to 5-7%, down from 7-9%.
Long-term target of $5 billion revenue by 2030 remains unchanged.
5. **Strategic Focus**
Continued investment in R&D and manufacturing capacity expansion to support growth.
Confidence in revised targets despite medium-term adjustments.
Hikma remains committed to its global strategy, focusing on innovation, partnerships, and operational efficiency to drive long-term growth. A Q&A webinar for analysts was announced to provide further details.